Study of Some biochemical markers associated with prognosis of Breast cancer in Iraqi women

Abstract

Background

    The prediction of treatment outcome in patients with advanced breast cancer remains a challenge. Even within the same stage, survival and response vary, so the goal of this study was to evaluate the prognostic value of systemic inflammatory markers available in the general laboratory including: C-reactive protein, D-dimer, Procalcitonin and Erythrocyte sedimentation rate in patients with breast cancer.

Methods:

Retrospective cohort study carried out between January 1, 2022 and May 31, 2023 with a total of 98 patients with different stages of breast cancer. From which the levels of the inflammatory markers C-reactive protein, D-dimer, Procalcitonin and Erythrocyte sedimentation rate were obtained prior to the first line ofchemotherapy, the study evaluates the correlation of basal levels and their variation with the response to treatment, the value of CRP and ESR in prognosis was also assessed.

Results:

 Ninghty eight patients with a mean age of 55 years (SD ± 12) were included; 70% were women, 83% had adenocarcinoma, 47% had more than two organs involved by metastasis and 89% had an IK > 70%. At the start of chemotherapy, 52%, 43%, 53% and 34% had abnormal levels of PC, DD, ESR and CRP, respectively. Patients with low ESR (p = 0.004), high DD (p = 0.012) and abnormal CRP (p = 0.040) had a worse overall response rate to first line chemotherapy.

Conclusions: CRP and Procalcitonin levels are independent prognostic factors for survival in patients with advanced breast cancer receiving chemotherapy